Development of selective and potent inhibitors of

There is ongoing collaboration with Prof. Michael Threadgill (University of Bath) on the development of poly(ADP-ribose)polymerase (PARP) inhibitors. PARP is an epigenetic regulator of DNA repair; inhibition of this enzyme is of tremendous interest in anticancer treatment and in preventing ischaemia-reperfusion injury following events such as stroke and myocardial infarction. I began this work during my doctoral research at Mike’s research group.[1,2] Currently we are working towards patent application of some of the more potent inhibitors. There is also interest in developing isofrom-selective inhibitors.